GlassScriptPhysician profile
Luminita M Mann
NPI 1326338450
$9,629.86
in general payments reported to CMS, 2019-2025
42 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,305 · 2022: $1,845 · 2023: $2,522 · 2024: $1,531 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,480.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,070.03 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,139.34 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $674.35 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $655.59 | 2021-2025 | |
| Abbott Laboratories | $485.41 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $468.34 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.13 | 2021-2025 | Jardiance |
| Amgen INC. | $404.61 | 2021-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $376.65 | 2021-2025 | Korlym |
| Abbvie INC. | $356.52 | 2021-2025 | |
| Insulet Corporation | $274.84 | 2021-2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $228.62 | 2021-2025 | |
| Ibsa Pharma INC. | $209.59 | 2021-2025 | Licart, Tirosint, Flector |
| Radius Health, INC. | $208.16 | 2021-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $189.56 | 2023-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $125.90 | 2022-2023 | Tepezza |
| Medtronic, INC. | $114.09 | 2021-2025 | Minimed 780g, Stealthstation S8 Platform |
| Grt US Holding, INC. | $112.38 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $95.68 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Embecta Corp. | $90.05 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Lifescan, INC. | $86.62 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $85.68 | 2023-2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $83.90 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $82.83 | 2024-2025 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $70.64 | 2021-2023 | Strensiq |
| Becton, Dickinson and Company | $61.33 | 2022 | |
| Madrigal Pharmaceuticals | $48.67 | 2025 | Rezdiffra |
| Mannkind Corporation | $44.76 | 2021-2025 | |
| Bigfoot Biomedical INC | $42.84 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $39.12 | 2022 | |
| Kyowa Kirin, INC. | $27.74 | 2025 | |
| Averitas Pharma INC. | $27.43 | 2023 | Qutenza |
| Cequr Corporation | $24.21 | 2023 | Cequr Simplicity |
| Astellas Pharma US INC | $23.97 | 2024 | Veozah |
| Sequel Med Tech, LLC | $21.16 | 2025 | Twiist |
| Antares Pharma, INC. | $20.20 | 2021 | |
| Esperion Therapeutics, INC. | $19.39 | 2021 | |
| Pfizer INC. | $17.57 | 2023 | |
| Merck Sharp & Dohme LLC | $17.30 | 2021 | |
| Currax Pharmaceuticals LLC | $13.94 | 2022 | |
| Amryt Pharma Holdings LTD | $13.36 | 2021 | |
| Ascensia Diabetes Care US INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luminita Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.